Currently, research efforts aimed at inhibiting HIF-1α activity and its related pathways are predominantly concentrated in the oncology domain, with a notable deficiency in studies pertaining to renal diseases, particularly DKD. Here, HIF1A is linked to diabetic kidney disease.